Literature DB >> 17020486

Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury.

Frank K H van Landeghem1, Thorsten Weiss, Manfred Oehmichen, Andreas von Deimling.   

Abstract

The primary mechanism for eliminating synaptically released glutamate is uptake by astrocytes. In the present study, we examined whether traumatic brain injury (TBI) affects the cellular expression of glutamate transporters EAAT1 and EAAT2. Morphometrical immunohistochemical analysis demonstrated a predominant expression of EAAT1 and EAAT2 in astrocytes of normal human neocortex (n = 10). Following traumatic injury of human brain (n = 55), the number of EAAT2-positive cells was decreased for a prolonged survival period within the traumatized neocortex and the pericontusional region. GFAP-positive astrocytes decreased in number within the first 24 h. Thereafter, the number of GFAP-positive astrocytes increased again, indicating formation of reactive gliosis. Double immunofluorescence examinations revealed a reduction in absolute numbers of GFAP-positive astrocytes coexpressing EAAT1 or EAAT2 at survival times up to 7 days. In addition, the relative fractions of astrocytes coexpressing glutamate transporters decreased following TBI. We conclude that the posttraumatic reduction in cellular EAAT 1 and EAAT2 expression is predominantly due to degeneration of astrocytes and to downregulation in surviving astrocytes. Our results support the view that reduced glutamate uptake by astrocytes contributes to posttraumatic elevation of extracellular glutamate in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020486     DOI: 10.1089/neu.2006.23.1518

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  55 in total

1.  Hypersensitive glutamate signaling correlates with the development of late-onset behavioral morbidity in diffuse brain-injured circuitry.

Authors:  Theresa Currier Thomas; Jason M Hinzman; Greg A Gerhardt; Jonathan Lifshitz
Journal:  J Neurotrauma       Date:  2011-12-01       Impact factor: 5.269

Review 2.  Neurotransmitter changes after traumatic brain injury: an update for new treatment strategies.

Authors:  Jennifer L McGuire; Laura B Ngwenya; Robert E McCullumsmith
Journal:  Mol Psychiatry       Date:  2018-09-13       Impact factor: 15.992

Review 3.  Traumatic brain injury: can the consequences be stopped?

Authors:  Eugene Park; Joshua D Bell; Andrew J Baker
Journal:  CMAJ       Date:  2008-04-22       Impact factor: 8.262

4.  Rosiglitazone attenuates cerebral vasospasm and provides neuroprotection in an experimental rat model of subarachnoid hemorrhage.

Authors:  Bo-Feng Lin; Chan-Yang Kuo; Li-Li Wen; Chun-Mei Chen; Ya-Feng Chang; Chih-Shung Wong; Chen-Hwan Cherng; Mei-Yu Chuang; Zhi-Fu Wu
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

5.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

6.  Glutamate affects dendritic morphology of neurons grown on compliant substrates.

Authors:  Michelle L Previtera; Bonnie L Firestein
Journal:  Biotechnol Prog       Date:  2015-04-08

Review 7.  Inflammation in acute CNS injury: a focus on the role of substance P.

Authors:  F Corrigan; R Vink; R J Turner
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

8.  Partial Loss of the Glutamate Transporter GLT-1 Alters Brain Akt and Insulin Signaling in a Mouse Model of Alzheimer's Disease.

Authors:  Kole D Meeker; James S Meabon; David G Cook
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 9.  The contribution of astrocytes and microglia to traumatic brain injury.

Authors:  Ila P Karve; Juliet M Taylor; Peter J Crack
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

10.  Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.

Authors:  Tanya Chotibut; Richard W Davis; Jennifer C Arnold; Zachary Frenchek; Shawn Gurwara; Vimala Bondada; James W Geddes; Michael F Salvatore
Journal:  Mol Neurobiol       Date:  2013-12-03       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.